

International Cancer Cluster Showcase 2014

June 22nd, 2014

San Diego Convention Center – Upper Level, Room 23

Kindly sponsored by:



1:00 – 1:30 p.m.

REGISTRATION

1:30 – 1:45 p.m.

Opening and Welcome

ICCS Organizing Partners

Andrea Cotton-Berry, Global Director Client Services, Ockham Oncology

1:45 – 2:10 p.m.

CQVB Québec, Canada

glcare Pharma

IRICoR

Kanyr Pharma

2:10 – 2:35 p.m.

Oslo Cancer Cluster, Norway

BerGenBio

Nextera

PCI Biotech

2:35 – 3:00 p.m.

Massachusetts Technology Transfer Center/Dana-Farber Cancer Institute, USA

BioArray Therapeutics

Amorsa Therapeutics

Cure Technologies

3:00 – 3:30 p.m.

Networking Break

3:30 – 4:00 p.m.

Cancer-Bio-Santé and Cancer Campus, France

Affichem

GamaMabs Pharma

Oncomedics

Axenis

4:00 – 4:25 p.m.

Chicago Cancer Cluster, USA

TriAct

Panther Biotechnology

LX Diagnostics

4:25 – 4:50 p.m.

Cancer Research UK and CRT, United Kingdom

Imanova

Areacor

BioMoti

4:50 – 5:00 p.m.

Poster Partner Presentations

Stockholm Uppsala Life Science

5:00 – 6:30 p.m.

Networking Reception and Poster Session

For more information please visit: www.internationalcancercluster.org



International Cancer Cluster Showcase 2014 – Presenting companies



Affichem AS is a biotech company founded in 2002 as a spin-off of INSERM whose mission is to optimize and develop regenerative therapeutic molecules and biomarkers for the treatment of cancer and neurodegenerative diseases. It based in Toulouse, city hosting the largest University cancer hospital in Europe. The first 3 proprietary molecules (AF122, 243 and 130) are aimed at markets that are major and/or unmet medical needs: acute myeloid leukemia, hearing loss and dermatology. Affichem is also developing a predictive biomarker of the therapeutic efficacy of anti-cancer drugs, AF300. AF300, intended for commercialization, but also for the optimization of internal clinical research, launches Affichem into the field of theranostics.

Contact: Michaël Paillasse, Head of innovation; T: +33 979 25 61 96; m.paillasse@affichem.com
www.affichem.fr



Amorsa is a drug development company focused on addressing the unmet medical need for an effective, safe and convenient treatment for refractory cancer pain. Approximately 25% of advanced cancer patients do not achieve acceptable levels of pain relief from conventional therapies. Amorsa is developing a novel patent-protected sustained release oral formulation of the FDA approved anesthetic, ketamine, for use in refractory cancer pain. Importantly, ketamine's mechanism of action and safety profile are well understood and its potent analgesic activity demonstrated through substantial off-label use is widely documented. Amorsa's new solid dose formulation will deliver extended release ketamine, as an adjuvant therapy with opioids, in an effective and convenient once-a-day tablet. Independent research reports estimate an annual peak sales potential of nearly \$600 million for an FDA approved product, such as Amorsa K-ER™, to treat refractory cancer pain.

Contact: Joe Blanchard, CEO; T: +1.774.249.9278; jblanchard@amorsatx.com
www.amorsatx.com



Arecor provides advanced technology in the stabilization of proteins, peptides and vaccines. Application of the technology enables improved products due to increase in stability and more convenient delivery options. One aspect of the technology allows formulating monoclonal antibodies at very high concentrations with minimal aggregation and low viscosity. This opens up opportunities for a switch from intravenous infusions to more convenient subcutaneous injections of a number of oncology drugs. Arecor's patented technology can provide valuable market differentiation for marketing companies, and user convenience for patients and practitioners. Arecor has partnered with the world's largest pharmaceutical companies to enable previously impossible delivery and use options for biologics.

Contact: Guy Hill, Senior Business Development Manager; T: +44 1223 426060; guy.hill@arecor.com
www.arecor.com



BerGenBio AS is developing first-in-class drugs for aggressive, drug resistant cancers. The Company is a world leader in understanding epithelial-mesenchymal transition (EMT) biology, a key pathway in cancer drug-resistance and metastasis. BerGenBio is developing a pipeline of novel EMT inhibitors. BGB324, is the first highly selective Axl kinase inhibitor in clinical development. Phase Ib trials starting H1 2014 will explore the use of the drug in acute myeloid leukaemia (AML) and non-small cell lung cancer (NSCLC). AXL Companion Dx, proprietary assays for patient segmentation and Pharmacodynamic profiling. BGB001 a series of multi format Axl mAb, BGB002 Small molecule against an undisclosed novel target.

Contact: Richard S. Godfrey, CEO; T: +47 91786304; richard.godfrey@bergenbio.com
www.bergenbio.com



BIOARRAY Therapeutics Inc. (BIOARRAY) is developing diagnostic tests to match a breast cancer patient with the right drug the first time. BIOARRAY's lead test has been shown to reduce ineffective treatments by over 50% in proof of concept studies. BIOARRAY is a recipient of Avon Foundation for Women and Connecticut Innovations funds. BIOARRAY was nominated the "Most Promising Life Science Product" by CT Technology Council and is a MassChallenge Accelerator Winner. Marcia Fournier, BIOARRAY's Founder and CEO, came to the United States from Brazil about 15 years ago. Marcia is trained in genetics with 10+ years of experience in cancer research. She most recently held a position at GlaxoSmithKline, Oncology Center of Excellence for Drug Discovery. Marcia's work as a doctoral fellow at the Dana-Farber Institute and postdoctoral fellow at UC Berkeley led to seminal publications on biomarker discovery.

Contact: Marcia V. Fournier, Founder and CEO; T: +1 860-679-7128; mvf@bioarray.us
www.bioarray.us



STOCKHOLM - JIPPSALA LIFE SCIENCE

International Cancer Cluster Showcase 2014 – Presenting companies



BioMoti exists to transform the lives of cancer patients by doing things differently. Oncojans™ are a new class of therapeutic microparticles that target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The Oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals. MOTI1001 is BioMoti's lead Oncojan™ based ovarian cancer candidate that has shown very promising potential in early preclinical studies.

Contact: Davidson Ateh, CEO; T: +44 20 7148 0923; davidson.ateh@biomoti.com
www.biomoti.com



Cure Technologies is focused on the development and manufacturing of specialized drug delivery systems designed enhance targeted and sustained drug delivery to both primary tumors and metastases, with extended drug release times up to 1-2 weeks. Several published studies have verified that the size, shape, and surface charge of various Nanoscale particles will control bio distribution and cellular uptake with more sustained drug release profiles, resulting in toxicity reduction and significant efficacy gains with several new siRNA's and existing work horse chemotherapeutics. By optimizing a combination of these factors with proprietary processing technologies, significant Cure Rates have been achieved on several highly metastatic animal models which have never before experienced a complete cure result.

Contact: Steve Klemm, President; T: 1-616-340-2593; srklemm@gmail.com



GamaMabs Pharma develops innovative monoclonal antibodies in cancer. GamaMabs' lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Mullerian Human Receptor II (AMHR2 also known as MISR2), an unaddressed specific target in ovarian cancer. The company values high-potential assets in oncology developed initially at LFB Biotechnologies. Those assets are essentially composed of an original patented platforms for the generation of mAbs with high efficiency (EMABling®) and patents related to the AMHR2 target. GamaMabs develops a pipeline stemming from those technologies, among them 3C23K currently in advanced pre-clinical stage. The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

Contact: M. Stephane Degove, CEO; T: +33 5 31 61 60 69; sdegove@gamamabs.com
www.gamamabs.com



gicare pharma Inc. is a late clinical-stage, GI specialty company which develops analgesic drugs providing adequate colonic analgesia in patients who undergo sedation-free colonoscopy. In the last decade, a major cost increase was observed in colonoscopy, mainly due to the extensive use of i.v. sedation. GIC-1001 is a novel alternative to replace costly deep and moderate sedation in colonoscopy and therefore, to increase colorectal cancer screening and surveillance. It aligns cost containment with visceral pain management, without any compromise on clinical outcomes.

Contact: Maxime Ranger, President and CEO; T:+1-514-825-9035; mranger@gicarepharma.com
www.gicarepharma.com



Imanova Limited - a centre of excellence in imaging sciences. Imanova is an innovative alliance between the UK's Medical Research Council and three world-class London Universities: Imperial College, Kings College and University College.

Contact: Kevin Cox, CEO; T: +44 7554436891; Kevin.Cox@imanova.com
www.imanova.co.uk



International Cancer Cluster Showcase 2014 – Presenting companies



IRICoR, the Institute for Research in Immunology and Cancer–Commercialization of Research, is a not-for-profit drug discovery and commercialization centre created in 2008 and based at Université de Montréal (UdeM). IRICoR is a fully-integrated centre under a single roof, with one of the largest academia-based industry-experienced medicinal chemistry groups in Canada. Our mission is to rapidly translate highly innovative and commercially promising projects from IRIC/UdeM/collaborating centres into high value novel therapies mainly in oncology and immunology. We support and invest in selected projects to rapidly transition them from academia to the market with the best targeted partners for development and financing. To date, we have established strategic alliances with pharmaceutical partners like Bristol-Myers Squibb and Pfizer and we also have small molecule programs and drug discovery enabling tools ready for partnering.

Contact: Nadine Beauger, Vice-President, Scientific Liaison; T: +1 514-343-6111 ext. 0315; nadine.beauger@iricor.ca; www.iricor.ca



Kanyr Pharma - A Montreal-based company with more than 15 years' experience in both drug discovery and biological investigation of the protein tyrosine phosphatase (PTP). Kanyr has identified several tractable PTP targets with strong biological validation at the lead ID stage. Our initial focus is on the phosphatase of regenerating liver (PRLs) PTPs for the treatment of colorectal cancer. PRLs are the most oncogenic enzymes of the PTP gene family. All PRLs promote cell proliferation, migration, invasion, tumor growth and metastasis. Kanyr has proprietary data on their mechanism of action allowing for the targeting of PRLs through a newly identified co-oncogenic partner, a novel and highly tractable approach to develop long sought after PRL inhibitors.

Contact: Daniel Bouthillier, President and CEO; T: +1 514-402-1764; daniel.bouthillier@kaneq.ca www.kaneq.com



LX Diagnostics - Colorectal cancer (CRC) is the second most common cancer in the US and incidence and mortality are even higher in the African American community. CRC screening has been found to save many lives and it is recommended to all persons who do not have a family history of cancer by age 50 (or 45 for AAs). Colonoscopy is the best test for screening but this is invasive and it carries some risks. Non-invasive tests are stool based, and not good at detecting early lesions. A blood based test that would diagnose a significant number of early cancers would be highly acceptable and would likely increase compliance with CRC screening. Micro RNAs are ideal markers for cancer as they are stable in blood plasma. Proof of concept studies have shown that a combination of markers is able to detect CRCs and some advanced polyps. The aim is to develop a reliable blood based test that will be highly accepted by the community and this will result in an increase in CRC screening with a subsequent decrease in CRC incidence and mortality.

Contact: Xavier Llor, Founder; 203-737-8062; xavier.llor@yale.edu



Nextera AS is a drug discovery company offering a new approach to immunotherapy. Nextera's unique technology platform enables discovery of novel disease-specific targets. The key innovative element is our unique Phagemer technology enabling antigen specific CD4+ T cell detection and epitope discovery of HLA class II dependent antigens. Nextera's business model is to use its proprietary platform as an "innovation engine" to discover new targets and subsequently develop first-in-class lead candidate drugs for cancer, autoimmune diseases and chronic infections. Targeting the disease early in the immunological cascade, we believe, will lead to more efficacious drugs with fewer side effects. The first chosen indication for Nextera is Crohn's Disease (CD).

Contact: Thomas Andersen, CEO; T: +47 97190312; thandersen@nextera.no www.nextera.no



International Cancer Cluster Showcase 2014 – Presenting companies



Oncomedics is a French innovative company founded in 2006 for personalized cancer care. Oncomedics has developed the Oncogramme, a standardized functional assay based on human primary cell cultures of tumor tissues. Oncogramme create a functional profile of a patient tumor's sensitivity and resistance to various drugs (or drug dandidate) and combinations to give to physician the most accurate information to treat patient's cancer. Our technology uses chemically-defined media to obtain reliable and standardized tumour models. Based on our expertise, Oncomedics has developed OncoTRIP™- Tumor Response Index & Profiling, a unique, centralized ex-vivo platform to profile new agents on tumor-derived primary cell cultures.

Contact: Christophe Lautrette, CEO; T. +33 6 18 00 75 76; c.lautrette@oncomedics.com
www.oncomedics.com



Panther Biotechnology is focused on the acquisition and development of small molecule therapeutics for the treatment of Leukemia, Lymphoma and Myeloma.

Contact: Richard Rainey; T: +1 (847)563-2349; info@pantherbiotechnology.com



PCI Biotech is a clinical stage, cancer-focused company listed on the Oslo Stock Exchange. The company is developing a technology platform, photochemical internalisation (PCI), which allows increased delivery of drugs through triggered endosomal release. This is a versatile platform that works with a wide array of modalities: small molecules, ADCs, siRNA, and antigens. PCI Biotech has currently two programs in clinical development: head and neck cancer (phase II) and cholangiocarcinoma (phase I). The technology can also be used as an adjuvant to therapeutic and prophylactic vaccines: we have demonstrated in vivo that PCI of antigens leads to a large increase in the number of antigen-specific Killer T-cells by enhancing MHC I presentation.

Contact: Per Walday, CEO; T: +47 917 93 429; pw@pcibiotech.com
www.pcibiotech.com



TriAct is a clinical stage cancer therapeutics company developing a portfolio of novel, small molecule, multi-kinase inhibitors to address the significant unmet needs of cancer patients who acquire resistance to approved therapies. TriAct's lead drug candidate, TT-100, inhibits EGFR, IGF-1R and cMET, simultaneously blocking growth signaling in each pathway and effectively denying tumor cells the chance to switch signaling between pathways as a means of acquiring resistance to approved therapies. TT-100 development is initially focused on high value lung cancer indications where the company believes its multi-kinase approach has the potential to significantly enhance the anti-tumor effects of current as well as next generation lung cancer therapies.

Contact: Thomas F. White , President & CEO Co-Founder, Board of Directors; tom.white@triactinc.com

Special thanks to:



Organizer contact:

MASSACHUSETTS: Abigail Barrow, abarrow@umassp.edu

QUEBEC: Richard Cloutier, Richard.cloutier@cqvbc.gc.ca

FRANCE: Celine Bedja, celine.bedja@cancerbiosante.fr

CHICAGO: David Klick, dklick@otm.uic.edu

NORWAY: Jutta Heix, jh@oslocancercluster.no

UK: Richard Hayhurst, richard@richardhayhurstassociates.com



International Cancer Cluster Showcase 2014 – Organizing partners

Massachusetts Technology Transfer Center - Massachusetts' unique ecosystem of leading research institutions, supporting organizations, and investor community spurs the creation of numerous new companies every year. Massachusetts' cancer expertise is maintained by cutting edge research at multiple institutions including the Dana-Farber Cancer Institute and the David Koch Institute for Integrative Cancer Research at MIT. Many of the newly formed companies in the Commonwealth focus on cancer diagnostics and treatment. The Massachusetts Technology Transfer Center is a non-profit organization that supports technology transfer activities from public and private research institutions to companies in Massachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.

Contact: Abigail Barrow, abarrow@umassp.edu; www.mattcenter.org

The **CQVB (Centre québécois de valorisation des biotechnologies)** is a unique organization, which stimulates and supports technology transfer and innovation within small to medium-sized bio-industry companies in Québec Province. The CQVB explores new opportunities for partnerships and promotes Québec's innovative assets and technologies. Québec's cancer expertise include 5 major universities, 7 affiliated research institutes, one dedicated network (135 researchers) and more than 20 companies involved in cancer research and product development from new targets and molecules to novel diagnostics and therapies

Contact: Richard Cloutier, Richard.cloutier@cqvb.qc.ca; www.cqvb.qc.ca

The **Chicago Cancer Cluster** represents three outstanding cancer centers located in the City of Chicago. The centers are affiliated with the largest research institutions and the best medical facilities in Illinois, where they deliver high levels of care and treatment to over 17,000 new cancer cases per year, and provide access to a substantial network of clinical trial sites. More than 700 researchers investigate better treatments for patients through \$280+ million per year in grant funding, which has yielded promising new technologies available for license and several notable startup companies. Learn more about the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, the University of Chicago Comprehensive Cancer Center, and the University of Illinois Cancer Center.

Contact: David Klick, dklick@otm.uic.edu

Oslo Cancer Cluster is a research and industry cluster focused on oncology. Organized as non-profit member organization Oslo Cancer Cluster is dedicated to accelerate the development of new cancer treatments. The 70 members represent the entire R&D value chain and include academic research institutes, university hospitals, innovative SMEs and international Pharma companies. The cluster's growing pipeline comprises innovative therapeutics and diagnostics including several novel cancer immunotherapies in preclinical and clinical development.

Contact: Jutta Heix, jh@oslocancercluster.no; www.oslocancercluster.no

A unique and broad approach throughout the continuum of cancer **Cancer-Bio-Santé Cluster**, located in Toulouse, is the French cluster in France fully dedicated to the fight against Cancer, throughout a broad continuum approach involving prevention, diagnostics, therapeutics and patient monitoring. CBS supports companies from the Midi Pyrénées and Limousin regions, which develop innovative products in the fields of food & Health, Diagnostics, Biomarkers, Nanotechnologies, Medical Devices, Immunotherapy, Therapeutics, Biotechnologies and Telemedicine. The mission of the Cancer-Bio-Santé cluster is to support companies to develop innovative products by synergizing public and private research and clinical research actors.

Contact: Celine Bedja, celine.bedja@cancerbiosante.fr; www.cancerbiosante.fr

Cancer Research UK is the world's leading charity dedicated to saving lives through research. The charity's groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. This work is funded entirely by the public. Cancer Research UK supports research into all aspects of cancer through the work of more than 4,800 scientists, doctors and nurses. Together with its partners and supporters, Cancer Research UK's vision is to beat cancer. Cancer Research Technology, Ltd. is the cancer-focused technology development and commercialization arm of Cancer Research UK.

www.cancertechnology.com

